Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $116.3 million.

  • Cytek Biosciences' Total Liabilities rose 1000.82% to $116.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.3 million, marking a year-over-year increase of 1000.82%. This contributed to the annual value of $103.8 million for FY2024, which is 233.74% up from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Total Liabilities is $116.3 million, which was up 1000.82% from $115.8 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Total Liabilities registered a high of $116.3 million during Q3 2025, and its lowest value of $46.9 million during Q2 2021.
  • In the last 5 years, Cytek Biosciences' Total Liabilities had a median value of $100.2 million in 2023 and averaged $91.0 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 7400.79% in 2022, then plummeted by 621.86% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Total Liabilities stood at $57.9 million in 2021, then skyrocketed by 62.17% to $93.9 million in 2022, then rose by 7.95% to $101.4 million in 2023, then grew by 2.34% to $103.8 million in 2024, then grew by 12.13% to $116.3 million in 2025.
  • Its Total Liabilities was $116.3 million in Q3 2025, compared to $115.8 million in Q2 2025 and $103.0 million in Q1 2025.